Program
tinengotinib
Also written as “TT-00420”, “TT-00420 (tinengotinib)” and “tinengotinib 10 mg QD plus darolutamide”.
Its studies are mostly in Cholangiocarcinoma · Prostatic Neoplasms · Breast Neoplasms · Carcinoma, Hepatocellular · Triple Negative Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| TransThera Sciences (Nanjing) | 105 open or running | phase 3since Jun 29, 2023 | Aug 21, 2018 | Dec 2026phase 3 · NCT05948475 |
| Akeso | 11 open or running | phase 2since Jun 26, 2025 | Jun 26, 2025 | May 10, 2027phase 2 · NCT07052253 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 21, 2018First study: phase 1 study in Triple Negative Breast NeoplasmsNew to TransThera Sciences (Nanjing)TransThera Sciences (Nanjing) · NCT03654547 · 48 enrolled · United States, China
- Jan 6, 2021Phase 1 study in HealthyTransThera Sciences (Nanjing) · NCT04705922 · 24 enrolled · United States
- Feb 2, 2021Phase 2 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT04742959 · 203 enrolled · United States
- May 27, 2021Phase 2 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT04919642 · 55 enrolled · United States
- Jan 26, 2022Phase 2 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT05253053 · 84 enrolled · China
- Jun 29, 2023Phase 3 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT05948475 · 200 enrolled · United States, Austria, Belgium and more
- Sep 5, 2023Phase 2 study in Cholangiocarcinoma MetastaticTransThera Sciences (Nanjing) · NCT06057571 · 50 enrolled · China
- Jun 26, 2025Akeso's first study: phase 2 study in Carcinoma, HepatocellularNew to AkesoAkeso · NCT07052253 · 100 planned · China
- Dec 26, 2025Phase 3 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT07328919 · 138 planned · China
- Mar 19, 2026Phase 2 study in Breast NeoplasmsTransThera Sciences (Nanjing) · NCT07498478 · 94 planned · China
- Oct 3, 2026Phase 2 study in Prostatic NeoplasmsTransThera Sciences (Nanjing) · NCT07871110 · 182 planned · China
Ahead
- Dec 2026Primary completion: phase 3 study in CholangiocarcinomaTransThera Sciences (Nanjing) · NCT05948475
- May 10, 2027Primary completion: phase 2 study in Carcinoma, HepatocellularAkeso · NCT07052253
- Jun 30, 2027Primary completion: phase 2 study in Breast NeoplasmsTransThera Sciences (Nanjing) · NCT07498478
- Dec 31, 2028Primary completion: phase 2 study in Prostatic NeoplasmsTransThera Sciences (Nanjing) · NCT07871110
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 11 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07871110Prostatic Neoplasms · China | 2 | Recruiting | TransThera Sciences (Nanjing) | Dec 31, 2028 | 182 |
| NCT07498478Breast Neoplasms · China | 2 | Recruiting | TransThera Sciences (Nanjing) | Jun 30, 2027 | 94 |
| NCT07328919Cholangiocarcinoma · China | 3 | Not yet recruiting | TransThera Sciences (Nanjing) | Dec 31, 2029 | 138 |
| NCT07052253Carcinoma, Hepatocellular · China | 2 | Recruiting | Akeso | May 10, 2027 | 100 |
| NCT06057571Cholangiocarcinoma Metastatic · China | 2 | Active, not recruiting | TransThera Sciences (Nanjing) | Jul 27, 2025 | 50 |
| NCT05948475Cholangiocarcinoma · United States, Austria, Belgium and more | 3 | Active, not recruiting | TransThera Sciences (Nanjing) | Dec 2026 | 200 |
| NCT05253053Cholangiocarcinoma · China | 2 | Completed | TransThera Sciences (Nanjing) | Aug 31, 2024 | 84 |
| NCT04919642Cholangiocarcinoma · United States | 2 | Completed | TransThera Sciences (Nanjing) | Feb 28, 2024 | 55 |
| NCT04742959Cholangiocarcinoma · United States | 2 | Completed | TransThera Sciences (Nanjing) | Feb 20, 2024 | 203 |
| NCT04705922Healthy · United States | 1 | Completed | TransThera Sciences (Nanjing) | Mar 7, 2021 | 24 |
| NCT03654547Triple Negative Breast Neoplasms · United States, China | 1 | Completed | TransThera Sciences (Nanjing) | Jan 31, 2023 | 48 |
How it is read
Names in the registry
- “TT-00420”, 4 entries
- “TT-00420 (tinengotinib)”, 3 entries
- “tinengotinib 10 mg QD plus darolutamide”, 1 entry
- “tinengotinib 10 mg QD (2-week on / 1-week off) plus darolutamide”, 1 entry
- “tinengotinib 10 mg QD plus enzalutamide”, 1 entry
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 6 studies
- Prostatic Neoplasms, 1 study
- Breast Neoplasms, 1 study
- Carcinoma, Hepatocellular, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.